BiotechTube
NRx Pharmaceuticals

NRx Pharmaceuticals

NRXPPhase 2
nrxpharma.com

NRx Pharmaceuticals is a public company (Nasdaq: NRXP) focused on developing life-saving treatments for suicidal depression, bipolar depression, and PTSD. Its core technology targets the brain's NMDA and 5-HT2A receptors with a non-hallucinogenic, non-addictive approach. Key achievements include positive Phase 2 data for NRX-101, FDA designations for its lead program, and the submission of an ANDA for NRX-100, positioning it as a leader in neuroplastic therapies for severe mental health crises.

Market Cap
$59.0M
-8.0% period
Pipeline
—
Patents
—
Publications
—

NRXP · Stock Price

USD 1.850.16 (-7.96%)

Historical price data

AI Company Overview

NRx Pharmaceuticals is a public company (Nasdaq: NRXP) focused on developing life-saving treatments for suicidal depression, bipolar depression, and PTSD. Its core technology targets the brain's NMDA and 5-HT2A receptors with a non-hallucinogenic, non-addictive approach. Key achievements include positive Phase 2 data for NRX-101, FDA designations for its lead program, and the submission of an ANDA for NRX-100, positioning it as a leader in neuroplastic therapies for severe mental health crises.

PsychiatryCentral Nervous SystemMental HealthPain

Technology Platform

Proprietary platform for safe modulation of the brain's NMDA and 5-HT2A receptors to treat suicidal depression and PTSD, using a non-hallucinogenic, non-addictive, dual-mechanism approach.

Funding History

2
Total raised:$40M
Debt$10MJun 15, 2022
PIPE$30MJun 15, 2021

Opportunities

First-mover advantage in the large, untreated market for suicidal bipolar depression with zero approved drugs.
Expansion of its NMDA platform into adjacent large markets like PTSD and chronic pain.
Potential near-term revenue generation through the HOPE Therapeutics clinic network and approval of NRX-100 (ketamine).

Risk Factors

High clinical trial risk for its lead Phase 2 candidate.
Dependence on future capital raises as a pre-revenue company.
Regulatory uncertainty for novel endpoints in suicidality.
Future commercial competition from established therapies and potential new market entrants.

Competitive Landscape

Competes in a space with no approved oral therapies for its lead indication. Faces competition from Johnson & Johnson's Spravato (esketamine) for suicidal depression and a fragmented landscape of ketamine clinics. Differentiates through its specific focus on bipolar depression, oral maintenance therapy, and a clinical claim of reducing drug-induced suicidality and akathisia.